Silodosin

證據等級: L5

預測適應症: 6 個

Silodosin: From Benign Prostatic Hyperplasia (BPH) to Ambras Type Hypertrichosis Universalis Congenita

One-Sentence Summary

Silodosin is a highly selective α1A-adrenergic receptor antagonist, clinically known for treating benign prostatic hyperplasia (BPH)-related lower urinary tract symptoms by acting on prostate/bladder-neck smooth muscle. The TxGNN model predicts a possible link to Ambras Type Hypertrichosis Universalis Congenita, a rare congenital hair-overgrowth disorder, but this is currently supported by 0 clinical trials and 0 publications, and the evidence pack itself flags no identifiable mechanistic connection.

Quick Overview

Item	Content
Original Indication	Not formally provided (`original_indications` is empty; `original_moa` is flagged as a data gap). Prediction-rationale text references silodosin's known action on prostate/bladder-neck smooth muscle, consistent with its established BPH use.
Predicted New Indication	Ambras Type Hypertrichosis Universalis Congenita
TxGNN Prediction Score	99.99% (global rank 153)
Evidence Level	L5 (model prediction only — no trials, no literature)
Norway Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data is not available in this evidence pack — it is explicitly listed as a data gap (DrugBank MOA query, severity High; TFDA label, severity Blocking). Based on the mechanistic notes attached to each prediction, silodosin is understood as a highly selective α1A-adrenergic receptor antagonist acting primarily on prostate and bladder-neck smooth muscle — the pharmacological basis for its known BPH use.

Ambras type hypertrichosis universalis congenita is a rare congenital disorder linked to chromosomal rearrangements near hair-follicle developmental genes (e.g., near TRPS1) — a biological pathway with no known intersection with α1A-adrenergic signaling. The evidence pack's own rationale field states directly that there is no identifiable mechanistic link here.

This should therefore be read as a pure embedding-similarity output from the TxGNN model, not a mechanistically grounded hypothesis. The same pattern holds across all six candidates in this pack: none have a plausible mechanistic rationale, none have clinical trials, and the one candidate with attached literature (rank 3, "malformation syndrome with odontal/periodontal component," 20 papers) was found on inspection to be an irrelevant keyword mismatch — none of those papers mention silodosin or α1-adrenergic pharmacology at all.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Norway Market Information

No market authorization records are currently available for silodosin (market status: Not Marketed; 0 authorizations on file).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale:

All six candidates in this evidence pack are TxGNN outputs only (Evidence Level L5), with no clinical trials and no mechanistically plausible rationale; the one candidate with associated literature turned out to be an unrelated keyword mismatch. There is currently no basis to advance any candidate for silodosin.

To proceed, the following is needed:

TFDA-equivalent label (warnings/contraindications) — currently a Blocking data gap (DG001)
Confirmed mechanism of action from DrugBank — currently a High-severity data gap (DG002)
Formal original-indication/approved-labeling data (currently empty in this pack)
Should any future TxGNN candidate for silodosin show a biologically plausible α1A-adrenergic mechanism, dedicated clinical-trial and literature evidence collection for that specific candidate before re-scoring
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.